Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137538 · ClinicalTrials.gov registry record · Phase 4
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT02137538: Completed Phase 4 study, sponsored by Stanford University.
NCT02137538 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02137538, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.
Interventions
- DRUG Anastrozole
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2009-11-18 |
| Est. Completion | 2018-06-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02137538
The ClinicalTrials.gov registry entry for NCT02137538 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anastrozole is the first listed.
NCT02137538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02137538 about?
NCT02137538 is a clinical study titled "Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole". The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the...
What is the current status of trial NCT02137538?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2009-11-18. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT02137538?
The interventions under investigation include: Anastrozole (DRUG), Letrozole (DRUG).
Who is sponsoring clinical trial NCT02137538?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.